BARCELONA, Spain I March 16, 2021 I La Merie Publishing released the 16th edition of its annual report about sales of recombinant biologics. The report2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologicsprovides a compilation of the sales data of originator and biosimilar recombinant therapeutic proteins and antibodies in the calendar year 2021. In addition, information about sales of novel biologics, i.e. gene & cell therapy and RNAi, is presented.
Global sales of branded originator biologics increased by 13.1 % to US$ 271 bln compared with the previous year. Antibody sales represented more than 80% of total biologics sales in 2021. The strong growth of antibody sales was driven by immuno-oncology antibodies (+20.6%), novel anti-inflammatory antibodies (+21.5%) and anti-SARS-CoV-2 antibodies. Blockbuster status with 2021 sales exceeding US$ 1 bln was achieved by 69 recombinant biologic therapeutics (71% antibodies).
Due to biosimilar erosion of sales of established therapeutic proteins such as erythropoietins, interferon, G-CSF, human growth hormone and FSH, these products are summarized in a new group of established therapeutic proteins.
Sales and growth rates of cancer antibodies were analyzed by subgroup, especially for the strongly growing class of PD-1 & PD-L1 antibodies. Development of sales of antibody-drug conjugates are also presented for the first time.
Methodology
Sales data were obtained from company publications and refer to innovative branded products. All sales data were converted from their original, reported currency into US$ using official currency exchange rates as of February 17, 2022. Sales figures represent the sum of revenues in all territories where the products are marketed. Growth rates mostly are presented as reported (in some cases on constant exchange rates).
What you will find in the report:
Biologics Sales per Class of Branded Originator Products
- Sales of Established Therapeutic Proteins 2012 – 2021
- Sales and Growth Rates of Cancer Antibodies by Subgroup 2012 – 2021
- Sales and Growth Rates of Other Anti-Inflammatory Antibodies by Therapeutic Area 2012 – 2021
- Sales of Antibody-Drug Conjugates by Product 2012 – 2021
- Published Biosimilar Sales 2021 by Company
- Published 2021 Sales of Other Biologics Based on DNA, RNAi & Cells
TOP 30 Company Ranking List for Innovator Biologics Sales 2021
Blockbuster Biologics in 2021 (by generic name)
- Biologic Product Sales 2021
- Cancer Antibodies
- Other Anti-Inflammatory and Anti-Autoimmune Antibodies
- Anti-TNF Antibodies
- Insulin and Insulin Analogs
- Cardiometabolic Antibodies
- Ophthalmic Antibodies
- Anti-Infective Antibodies
- Established Therapeutic Proteins
- Recombinant Coagulation Factors
- Enzyme Replacement Therapy (ERT)
- Migraine Antibodies
- Other Proteins: Cardiometabolic, Cancer & Various Others
- Selected Biosimilar Antibodies & Proteins
- Other Biologics: DNA, RNA & Cells
The report 2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics can be acquiredat La Merie Publishing’s online store www.lamerie.com: https://lamerie.com/report/2021-sales-of-recombinant-therapeutic-antibodies-proteins-biosimilars-other-biologics/
For those interested in historic sales data of biologics, La Merie Publishing offers a subscription to its online Sales Database for Therapeutic Antibodies & Proteins: 1-Year Subscription at https://lamerie.com/report/sales-database-for-therapeutic-antibodies-proteins-1-year-subscription/. Subscription to the database includes a pdf copy of the most recent report about Biologics Sales.
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.
To leverage iexpertise and knowledge accumulated in the in-house database, La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.
SOURCE: La Merie Publishing
Post Views: 351
BARCELONA, Spain I March 16, 2021 I La Merie Publishing released the 16th edition of its annual report about sales of recombinant biologics. The report2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologicsprovides a compilation of the sales data of originator and biosimilar recombinant therapeutic proteins and antibodies in the calendar year 2021. In addition, information about sales of novel biologics, i.e. gene & cell therapy and RNAi, is presented.
Global sales of branded originator biologics increased by 13.1 % to US$ 271 bln compared with the previous year. Antibody sales represented more than 80% of total biologics sales in 2021. The strong growth of antibody sales was driven by immuno-oncology antibodies (+20.6%), novel anti-inflammatory antibodies (+21.5%) and anti-SARS-CoV-2 antibodies. Blockbuster status with 2021 sales exceeding US$ 1 bln was achieved by 69 recombinant biologic therapeutics (71% antibodies).
Due to biosimilar erosion of sales of established therapeutic proteins such as erythropoietins, interferon, G-CSF, human growth hormone and FSH, these products are summarized in a new group of established therapeutic proteins.
Sales and growth rates of cancer antibodies were analyzed by subgroup, especially for the strongly growing class of PD-1 & PD-L1 antibodies. Development of sales of antibody-drug conjugates are also presented for the first time.
Methodology
Sales data were obtained from company publications and refer to innovative branded products. All sales data were converted from their original, reported currency into US$ using official currency exchange rates as of February 17, 2022. Sales figures represent the sum of revenues in all territories where the products are marketed. Growth rates mostly are presented as reported (in some cases on constant exchange rates).
What you will find in the report:
Biologics Sales per Class of Branded Originator Products
- Sales of Established Therapeutic Proteins 2012 – 2021
- Sales and Growth Rates of Cancer Antibodies by Subgroup 2012 – 2021
- Sales and Growth Rates of Other Anti-Inflammatory Antibodies by Therapeutic Area 2012 – 2021
- Sales of Antibody-Drug Conjugates by Product 2012 – 2021
- Published Biosimilar Sales 2021 by Company
- Published 2021 Sales of Other Biologics Based on DNA, RNAi & Cells
TOP 30 Company Ranking List for Innovator Biologics Sales 2021
Blockbuster Biologics in 2021 (by generic name)
- Biologic Product Sales 2021
- Cancer Antibodies
- Other Anti-Inflammatory and Anti-Autoimmune Antibodies
- Anti-TNF Antibodies
- Insulin and Insulin Analogs
- Cardiometabolic Antibodies
- Ophthalmic Antibodies
- Anti-Infective Antibodies
- Established Therapeutic Proteins
- Recombinant Coagulation Factors
- Enzyme Replacement Therapy (ERT)
- Migraine Antibodies
- Other Proteins: Cardiometabolic, Cancer & Various Others
- Selected Biosimilar Antibodies & Proteins
- Other Biologics: DNA, RNA & Cells
The report 2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics can be acquiredat La Merie Publishing’s online store www.lamerie.com: https://lamerie.com/report/2021-sales-of-recombinant-therapeutic-antibodies-proteins-biosimilars-other-biologics/
For those interested in historic sales data of biologics, La Merie Publishing offers a subscription to its online Sales Database for Therapeutic Antibodies & Proteins: 1-Year Subscription at https://lamerie.com/report/sales-database-for-therapeutic-antibodies-proteins-1-year-subscription/. Subscription to the database includes a pdf copy of the most recent report about Biologics Sales.
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.
To leverage iexpertise and knowledge accumulated in the in-house database, La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.
SOURCE: La Merie Publishing
Post Views: 351
